HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof
AssigneePDS Biotechnology Corporation
InventorsFrank Bedu-Addo, Greg Conn, Martin Ward, Jerold Woodward
Life of this patent
Estimating the term…
Abstract
Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and cross-presented to T-cells. The peptides utilized in the compositions display high levels of binding with HLA-supertypes. The immunogenic compositions are broadly applicable to large proportions of target populations. The compositions comprise adjuvants such as cationic lipids.
Claims10
A CD8+ T-cell activating HPV therapeutic vaccine composition comprising peptide antigens and an adjuvant,
- wherein the peptide antigens consist of four different long HPV peptides:
- a peptide comprising SEQ ID NO:
- 5, a peptide comprising SEQ ID NO:
- 9, a peptide comprising SEQ ID NO:
- 10, and a peptide comprising SEQ ID NO:
- 11, or lipidated versions thereof,
- wherein each individual peptide has a binding affinity of approximately IC50 of 5,000 nM with 5 HLA supertypes, wherein the peptides are multi-epitope peptides,
- and wherein the adjuvant comprises a cationic lipid.
Dependencies are inferred from the claim text.